Finkelstein Thompson LLP Announces Investigation Of Ev3 Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ev3 Inc. (“ev3” or the “Company”) (Nasdaq:EVVV) arising from the Company’s announcement of its intent to be acquired by Covidien plc (“Covidien”). Under the terms of the agreement, ev3 shareholders will receive $22.50 in cash for every share of ev3 stock they own in a transaction valued at approximately $2.6 billion.

The investigation is focused on the potential unfairness of the consideration to ev3’s shareholders and the process by which ev3’s Board of Directors considered and approved the transaction. Specifically, at least one analyst has set a target price of $27 per share for the Company’s stock, and ev3 shares have increased by over forty percent in the last year.

If you are interested in discussing your rights as an ev3 shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at [phone] or by email at [e-mail].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

>To order reprints of this article, click here: Reprints